Göçer Mesut, Kurtoğlu Erdal
Department of Hematology, Antalya Training and Research Hospital, Antalya, Turkey.
Blood Res. 2020 Dec 31;55(4):206-212. doi: 10.5045/br.2020.2020158.
Ibrutinib is an oral irreversible Bruton's tyrosine kinase inhibitor. Here, we demonstrate the efficacy and safety of ibrutinib using real-life data from patients with marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), Waldenstr?m macroglobulinemia (WM), and follicular lymphoma (FL), especially in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
This is a retrospective, observational, non-interventional, and single-center study on 32 patients who received ibrutinib treatment between January 2017 and March 2020 regardless of their diagnosis.
Of the 32 patients, 11 had CLL and 21 had other B-cell lymphomas. Patients with CLL were prescribed ibrutinib for a median of 4 months (range, 2?18). In this group, diarrhea was observed in 3 (27.3%), pneumonia in 3 (27.3%), and thrombocytopenia and/or neutropenia in 2 (18.2%) patients. The overall response rate (ORR) was 85.6 % [28.5 % complete response (CR) and 57.1 % partial response (PR)] in the final response assessment during treatment with ibrutinib. Among other types of B-cell lymphoma, seven (33.4%) of the 21 patients were diagnosed with MCL, 5 (23.8%) with DLBCL, 4 (19.0%) with MZL, 3 (14.3%) with WM, and 2 (9.5%) with FL, upon follow-up. The median treatment duration was 4 months (range, 1?28) in this group. The most common adverse event was diarrhea: 8 (38.1%) patients. The ORR was 66.6% (20.0% CR and 46.6% PR) in the final response assessment during the treatment.
Ibrutinib is a good treatment option for CLL and other B-cell lymphomas, with an acceptable side effect profile, and high and promising CR/PR response rates. Ibrutinib treatment at an early stage decreases the burden of cytotoxic therapy in fragile patients, thereby, increasing their quality of life.
伊布替尼是一种口服不可逆的布鲁顿酪氨酸激酶抑制剂。在此，我们利用来自边缘区淋巴瘤（MZL）、弥漫性大B细胞淋巴瘤（DLBCL）、华氏巨球蛋白血症（WM）和滤泡性淋巴瘤（FL）患者的真实数据，尤其是慢性淋巴细胞白血病（CLL）和套细胞淋巴瘤（MCL）患者的数据，来证明伊布替尼的疗效和安全性。
这是一项回顾性、观察性、非干预性的单中心研究，研究对象为2017年1月至2020年3月期间接受伊布替尼治疗的32例患者，无论其诊断结果如何。
32例患者中，11例患有CLL，21例患有其他B细胞淋巴瘤。CLL患者服用伊布替尼的中位时间为4个月（范围为2至18个月）。该组中，3例（27.3%）出现腹泻，3例（27.3%）出现肺炎，2例（18.2%）出现血小板减少和/或中性粒细胞减少。在伊布替尼治疗期间的最终疗效评估中，总缓解率（ORR）为85.6%[完全缓解（CR）率为28.5%，部分缓解（PR）率为57.1%]。在其他类型的B细胞淋巴瘤中，随访时21例患者中有7例（33.4%）被诊断为MCL，5例（23.8%）为DLBCL，4例（19.0%）为MZL，3例（生14.3%）为WM，2例（9.5%）为FL。该组的中位治疗时间为4个月（范围为1至28个月）。最常见的不良事件是腹泻：8例（38.1%）患者出现腹泻。在治疗期间的最终疗效评估中，ORR为66.6%（CR率为20.0%，PR率为46.6%）。
伊布替尼是CLL和其他B细胞淋巴瘤的良好治疗选择，具有可接受的副作用谱，以及较高且有前景的CR/PR缓解率。早期使用伊布替尼治疗可减轻脆弱患者的细胞毒性治疗负担，从而提高他们的生活质量。
